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Toxic epidermal necrolysis (TEN) and Stevens-
Johnson syndrome (SJS) are acute life-threatening 
conditions, most often elicited by drugs and less 
often by infection.[1] SJS and TEN are characterised 
primarily by acute skin blisters and mucous membrane 
erosions.[2]The main difference between the two conditions is the 
extent of skin detachment: <10% in SJS and >30% in TEN.[3] Cases 
with detachment of 10 - 30% are labelled as SJS-TEN overlap.[1] Both 
SJS and TEN are rare and have an incidence of approximately 2 per 
million population per year in Europe.[4,5]
Typically, the drug reaction develops within the first 6 weeks after 
the causative drug initiation.[1,6-9] Initial symptoms are cough, fever, 
sore throat and facial swelling. If not detected early, and the offending 
drug discontinued, skin rash may develop that leads to skin ulcers 
and skin sloughing. Death of the patient could result.[10]
Numerous drugs can cause SJS, with several antituberculosis 
drugs,[11] aromatic anticonvulsants (e.g. carbamazepine, phenobarbital 
and phenytoin), anti-inflammatory drugs (e.g. allopurinol, 
chlormezanone), anti-infective agents (e.g. aminopenicillins, 
sulphonamides, quinolones, cycline antibiotics)[7,12] and antiretroviral 
(ARV) medications (e.g. nevirapine (NVP), zidovudine (AZT), 
stavudine (d4T), indinavir, didanosine)[7] being some of the most 
frequent offending agents.
It is important to note that although the outcome of SJS is not 
significantly worsened by HIV infection, HIV-infected patients 
have a higher predisposition to the condition because of decreased 
anti-oxidant levels owing to infection.[13,14] In addition, the greater 
likelihood of such patients using the drugs at higher dosages than the 
general population, further predisposes them to SJS.[7,15]
Although the first ARV agent was licensed in 1987, South 
Africa (SA) only began antiretroviral therapy (ART) in 2003. At 
that time, ARV use was guided by the National Department of 
Health’s Operational Plan for Comprehensive HIV and AIDS Care, 
Management, and Treatment; this plan was revised in 2010.[16-18] The 
revised plan states that all patients requiring ART must be initiated 
on first-line ARV regimens involving 3 ARVs in combination.[19,20] 
The recommended SA first-line regimens contain the following 
3-drug combinations: d4T, AZT or tenofovir with lamivudine and 
efavirenz (EFV) or NVP. Of these ARVs, NVP has been implicated as 
the cause of SJS in HIV-infected patients.[6,7,12,21]
In 1998, Barner and Myers from Boehringer Ingelheim 
Pharmaceuticals Inc. publicly acknowledged that NVP might cause 
SJS in some patients.[8] This adverse drug reaction is described in the 
labelling of NVP produced by this company, as well as that produced 
by other pharmaceutical companies, such as Cipla. A prominent 
warning to reduce the risk of rash of any severity (including SJS) is also 
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specified on NVP package inserts, whereby a 2-week lead-in dose (200 
mg once daily) is recommended. Furthermore, it is specified that the 
NVP dose should not be increased during the lead-in period until any 
rash that develops, has resolved. Reported risk factors for SJS include 
female sex, history of drug allergy, low body weight, high NVP plasma 
level and CD4 counts >250 cells/µl in women and >400 cells/µl in men.
[6,22] The revised SA plan on the use of ARVs recommends the use of 
NVP, even at a CD4 count >250 cells/ µl in pregnant women,[19,20] in line 
with the World Health Organization (WHO)’s contention that benefits 
outweigh risks of using the drug at a high CD4 count.
Recently, we became aware of a possible increase in risk of SJS among 
HIV-infected pregnant women taking NVP-containing ARV regimens 
in KwaZulu-Natal Province. This is a new observation, as pregnancy 
has not been specified by pharmaceutical companies as a risk factor 
for skin reactions. This increase in SJS incidence led to the release of a 
directive by the SA National Department of Health on 6 April 2012 (later 
retracted owing to lack of sufficient evidence) stating the following: (i) 
When initiating non-pregnant HIV-positive women of reproductive age 
on highly active ART (HAART), use EFV; (ii) when initiating treatment 
on HIV-positive pregnant women, use EFV if commencing treatment 
during the second trimester; (iii) delay initiation of treatment until the 
second trimester even in those women who need HAART and present 
during their first trimester; (iv) for HIV-positive pregnant women 
already on EFV as part of a HAART regimen, continue with EFV.
We investigated whether pregnancy was a risk factor for SJS 
among HIV-infected women monitored by the Medunsa National 
Pharmacovigilance Centre and taking NVP-containing regimens.
Methods
Study setting and study design
A matched case-control study with 5:1 matching was conducted at 
3 sentinel sites in the SA public health sector, located in Gauteng, 
Mpumalanga and Limpopo provinces. The study population 
comprised HIV-infected women >15 years old who had been taking 
NVP-containing ARV regimens and whose details were available on 
the Medunsa Pharmacovigilance Centre database. Excluded from the 
study population were women on the Prevention of Mother To Child 
Transmission (PMTCT) programme and women not taking NVP-
containing regimens.
Cases were those women who developed SJS within a period of 
3 - 46 days (6 weeks) after HAART initiation and were diagnosed 
as having SJS by the attending physician as stated on the case report 
form (CRF) or adverse drug reaction (ADR) form.
Controls were the population of reports not selected as cases and 
reported over a 5-year period where the subject was a woman on 
NVP-containing regimens and not diagnosed as having SJS. Controls 
were matched for age (within 5 years of the case), CD4 count (<250 
cells/ml or ≥250 cells/ml), and duration of NVP treatment (within 
one year of case). As there were no controls available with a closer 
match for duration of NVP treatment to that of cases (i.e. 3 - 46 days), 
a maximum of one year of treatment duration was used for controls.
Pregnancy status during NVP treatment was recorded for both the 
cases and the controls.
Data collection
All female patients taking NVP-containing regimens as part of 
HAART were selected from the database. All patients with ‘Stevens-
Johnson syndrome’ stated in the adverse drug reaction column were 
selected as cases. To ensure that no SJS cases were missed, ADR forms 
were simultaneously reviewed, and additional cases found that met 
the inclusion criteria were classified as cases.
Controls were selected among the female patients taking NVP-
containing regimens as part of HAART who had not been selected 
as cases. The selection of controls was based on the assumption that 
women taking NVP-containing regimens who were reported for an 
adverse event other than SJS were representative of all women taking 
NVP who had not been reported for SJS. For each case, the following 
procedure was performed in selecting appropriate controls: The age 
group, CD4 count and duration of treatment of the case were identified 
and a subset of potential controls was selected such that all elements 
had the same age group (within ±5 years of the case), CD4 count (<250 
cells/ml or ≥250 cells/ml) and duration of treatment (within ±1 year of 
the case) characteristics of the case. This process was carried out using 
Stata's ‘Keep’ command for each of the cases. One file resulted for each 
case and its controls. Stata's random sampling function was then used to 
select a random sample of 5 controls from each of the case files, in turn.
Data management and analysis
An algorithm for implicating a drug as the cause of an adverse drug 
reaction, described by Roujeau and Stern, was used to implicate NVP 
as the cause for SJS in this study:[1]
1. Alternative causes (e.g. concomitant medication) were 
excluded.
2. The interval between the introduction of a drug and the onset 
of a reaction was examined (for drug-induced SJS, 3 - 46 days 
was applied).
3. Any improvement after drug withdrawal was noted.
4. Any reaction if the drug were re-administered was noted.
Conditional logistic regression analysis was performed on STATA 
version 12 (StataCorp LP, College Station, TX, USA). Odds ratios, 
chi-square and 95% confidence intervals (CIs) were also computed. 
A p-value <0.05 was considered statistically significant.
Ethical approval
The project proposal, which includes the work described in this 
paper, was approved by the Medunsa Research and Ethics Committee 
of the University of Limpopo in 2006.
Results
Of the 2 664 patients enrolled from the 3 facilities during the study 
period, 10.4% (278/2 664) of female patients were taking NVP-
containing regimens. Of these patients, 6 SJS cases (6/278 (2.2%)) 
were identified from the database and ADR forms. Three cases were 
from Hospital A, 2 from Hospital B and 1 from Hospital C. The 
demographic characteristics of these 6 cases and 30 controls are 
shown in Table 1. Controls were selected to be as similar as possible 
to the cases; however, the cases were on treatment for between 3 and 
46 days before developing SJS.
Onset of SJS ranged from 18 to 31 days after initiation of NVP, 
with the highest frequency of patients experiencing SJS signs and 
symptoms after 24 days of drug administration (Fig. 1). For all cases, 
NVP was stopped and an alternative drug substituted, following 
which all SJS signs and symptoms subsided.
The characteristics of cases and controls with respect to pregnancy 
are shown in Table 2. Pregnancy increased the chances of developing 
SJS 14-fold (OR 14.28). This association was highly significant 
(p=0.006) despite the CI being wide owing to the small sample size 
(95% CI 1.54 - 131.82).
Discussion
Drug causality of SJS is easy to postulate but difficult to prove, 
particularly in HIV-infected patients on combination therapy and 
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other concomitant medicines. The toxicity of NVP during pregnancy 
has not been measured in large cohorts and, for those who have 
measured it, results are contradictory. Our results were based on 
attending physician diagnoses as logged in our CRF and ADR forms 
as well as a causality algorithm described by Roujeau and Stern.
Our findings show that the chance of developing SJS increases with 
pregnancy. This finding contradicts results found by Marazzi et al. 
(2006)[23] that NVP-containing regimens in pregnant women appear 
to be safe in African settings. In SA, most HIV-infected patients are 
initiated on an EFV-containing regimen and continue on that course 
unless they exhibit an adverse reaction. Patients who are pregnant, 
HIV-infected and in need of ARVs for their own health, are fast-tracked 
and initiated on an NVP-containing regimen. The standard prescribing 
practice is to switch patients from an EFV- to a NVP-containing 
regimen when they become pregnant, owing to possible teratogenicity 
that is attributed to EFV. This practice of prescribing NVP to pregnant 
women may account for the fact that these women are at a higher risk 
of developing SJS than the general population of women.
A weakness of this study was the small sample size which limited 
our study power. In addition, there were no controls available with 
a closer match for duration of NVP treatment to that of cases; 
consequently, a longer treatment duration for controls was used. In 
view of these weaknesses and our findings, further studies of this 
important matter are necessary before general conclusions can be 
reached. In addition to studying the association between SJS, NVP 
and pregnancy, the teratogenic effects of EFV should be thoroughly 
investigated to allow the SA National Department of Health to make 
an informed decision regarding safety of NVP in pregnancy.
Conclusion
The present analysis was performed to confirm or disprove suspicions 
of increased SJS among pregnant women taking NVP-containing 
regimens. Our investigation confirms this suspicion. Healthcare 
workers must therefore be advised to offer informed consent to 
the patient and recommend effective appropriate contraception 
methods if NVP treatment is considered. All other patients on NVP-
containing regimens must be equally closely monitored and NVP 
discontinued immediately if side-effects are experienced. Further 
studies are needed before the SA National Department of Health 
will be able to reach conclusions regarding NVP safety in pregnancy.
Acknowledgements. We acknowledge support from the SA National 
Department of Health. The Foundation for Professional Development 
contributed to the development of the database. Professor Mojakgomo 
H Motswaledi assisted with obtaining patient files of SJS cases. Professor 
Brendan V Girdler-Brown assisted with advice on the statistical analysis of 
the results. Dr Theresa Rossouw assisted with the review of this manuscript. 
The contents of this manuscript are solely the responsibility of the authors.
Authors’ contributions. N Dube and R Summers conceived this study. 
N Dube and E Adewusi reviewed ADR forms and CRFs and undertook 
data extraction. N Dube was involved in the statistical analysis and the 
interpretation of the results. All authors participated in the preparation 
and revision of this study.
References
1. Kumar PNS, Thomas B, Kumar K, Kumar S. Stevens-Johnson syndrome − toxic epidermal necrolysis 
(SJS-TEN) overlap associated with carbamazepine use. Indian J Psychiatry 2005;47(2):121-123. [http://
dx.doi.org/10.4103/0019-5545.55961]
2. Chen KT, Twu SJ, Chang HJ, Lin RS. Outbreak of Stevens-Johnson syndrome/toxic epidermal 
necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan. 
Am J Public Health 2003;93(3):489-492. [http://dx.doi.org/10.2105/AJPH.93.3.489]
3. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the 
risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001;15(14):1843-1848. [http://
dx.doi.org/10.1097/00002030-200109280-00014]
Table 1. Demographic characteristics of cases and controls 
identified at 3 sentinel sites, 2007 - 2012
Characteristics Cases (N=6) Controls (N=30)
Age (years)
Median 29 29
Interquartile range 27 - 33 27 - 34
Range 25 - 43 25 - 41
CD4 count (cells/μl)
Average 237 234
Median 199 222
Range 5 - 490 13 - 640
Duration of treatment (days)
Median 27 191
Interquartile range 21 - 30 112 - 283
Range 18 - 31 1 - 365
Table 2. Pregnancy characteristics of cases and controls identified at 3 sentinel sites, 2007 - 2012
Characteristics
Case patients (N=6) 
n (%)
Control patients (N=30) 
n (%)
Conditional logistic regression
Odds ratio (95% CI) Chi-square p-value
Pregnant
   Yes 5 (83) 7 (23) 14.28 (1.54 - 131.82) 7.56 0.006
   No 1 (17) 23 (77)
0
1
2
0-4 5-9 10-14 15-19 20-24 25-29 30-34
Days between drug initiation and onset of SJS
Fig. 1. Days between drug initiation and onset of SJS among cases, 
2007 - 2012.
RESEARCH
4. Pereira F, Mudgil A, Rosmarin D. Toxic epidermal necrolysis. J Am Acad Dermatol 2007;56:181-200. 
[http://dx.doi.org/10.1016/j.jaad.2006.04.048]
5. Bastuji-Garin S, Zahedi M, Guillaume JC, Roujeau JC. Toxic epidermal necrolysis (Lyell syndrome) 
in 77 elderly patients. Age Ageing 1993;22(6):450-456. [http://dx.doi.org/10.1093/ageing/22.6.450]
6. Metry DW, Lahart CJ, Farmer KL, Hebert AA. Stevens-Johnson syndrome caused by the 
antiretroviral drug nevirapine. J Am Acad Dermatol 2001;44(2):354-357. [http://dx.doi.org/10.1067/
mjd.2001.101885]
7. Rotunda A, Hirsch RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of 
human immunodeficiency virus medications. Acta Derm Venereol 2003;83(1):1-9. [http://dx.doi.
org/10.1080/00015550310002611]
8. Barner A, Myers M. Nevirapine and rashes. Lancet 1998;351(9109):1133. [http://dx.doi.org/10.1016/
S0140-6736(05)79417-4]
9. Yap FBB, Wahiduzzaman M, Pubalan M. Stevens-Johnson syndrome (SJS) and Toxic epidermal 
necrolysis (TEN) in Sarawak: A four years' review. EDOJ 2008;4(1):13.
10. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic 
epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002;8(1):5.
11. Kannenberg SMH, Jordaan HF, Koegelenberg CFN, Von Groote-Bidlingmaier F, Visser WI. Toxic 
epidermal necrolysis and Stevens-Johnson syndrome in South Africa: A 3-year prospective study. Q J 
Med 2012;105(9):839-846. [http://dx.doi.org/10.1093/qjmed/hcs078]
12. Mockenhaupt M, Liboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal 
necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-
study. J Invest Dermatol 2008;128(1):35-44. [http://dx.doi.org/10.1038/sj.jid.5701033]
13. Saiag P, Caumes E, Chosidow O, Revuz J, Roujeau JC. Drug-induced toxic epidermal necrolysis 
(Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 
1992;26(4):567-574. [http://dx.doi.org/10.1016/0190-9622(92)70082-Q]
14. Moreno-Ancillo A, Lopez-Serrano MC. Hypersensitivity reactions to drugs in HIV-infected patients. 
Allergic evaluation and desensitization. Clin Exp Allergy 1998;28:57-60.
15. Porteous DM, Berger TG. Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic 
epidermal necrolysis) in human immunodeficiency virus. Arch Dermatol 1991;127(5):740-741. 
[http://dx.doi.org/10.1001/archderm.1991.01680040152024]
16. World Health Organization. Rapid advice: Antiretroviral therapy for HIV infection in adults and 
adolescents. 2009. http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf (accessed 9 December 2012).
17. Mahumane C, Dube NM, Mayayise G, Summers S. An Overview of the Demographic Data from the 
Structured Surveillance Study. Ga-Rankuwa: Medunsa National Pharmacovigilance Centre, 2011.
18. National Department of Health. South African National Antiretroviral Treatment Guidelines (2010). 
Pretoria: National Department of Health, 2010. http://www.uj.ac.za/EN/CorporateServices/ioha/
Documentation/Documents/ART%20Guideline.pdf (accessed 9 May 2012).
19. National Department of Health. Clinical Guidelines for the Management of HIV & AIDS in Adults and 
Adolescents. Pretoria: Department of Health, 2010. http://www.fidssa.co.za/Guidelines/2010_Adult_
ART_Guidelines.pdf (accessed 9 December 2012).
20. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV 
Infection in Infants: Towards Universal Access. Geneva: World Health Organization, 2010. http://
whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf (accessed 9 December 2012).
21. Namayanja GK, Nankya JM, Byamugisha JK, et al. Stevens-Johnson syndrome due to nevirapine. Afr 
Health Sci 2005;5(4):338-340.
22. Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, et al. Incidence and risk factors of nevirapine-
associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL. Int J STD 
AIDS 2007;18(11):782-786. [http://dx.doi.org/10.1258/095646207782212289]
23. Marazzi MC, Germano P, Liotta G, et al. Safety of nevirapine‐containing antiretroviral triple therapy 
regimens to prevent vertical transmission in an African cohort of HIV‐1‐infected pregnant women. 
HIV Med 2006;7(5):338-344. [http://dx.doi.org/10.1111/j.1468-1293.2006.00386.x+]
Accepted 21 January 2013.
HPV A5 Advert.indd   1 15/04/2013   13:26:19
